Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

SAB Biotherapeutics, Inc.SABSW · healthcare
GradeNonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $172.8M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsshort runway, thin data, degenerate inputsnot computable: dilution, distress, fortress balance sheet
Inputs computable4 of 14
Graded fromfilings received through Mar 9, 2026214 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.032026-08-24; market equity $0; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$0.02$0.04NovDecJanFebMarAprMayJunJulAugSepOct$0.01
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2021nonen/aQ1
Apr 21, 2022nonen/aQ2
Mar 21, 2026nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 9, 2026; the document on sec.gov.

We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Warnings [top]

Short runway. cash runway is 1.8 months[3]
Thin data. 4 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 98.2
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio53.5%[1,4-6](6.6%)98.28112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 16.0
Twelve-month failure probabilitynot computable0.07%
firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime6.90[1,7-12](0.31)14.47562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio9.46x[7-8]2.96x17.68392025-12-31
Growth and financing, sleeve percentile 7.9
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years50.3%[1,6,13-14]2.1%7.97042025-12-31
Net share issuance, one yearnot computable2.5%
firm-wide XBRL shares cannot be assigned to one ticker class

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-08-24 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month1.3%8.0%47hotter than 47 of 100 peers
Distance from 52-week high(81.6%)(31.4%)8closer to its high than 8 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yieldnot computable(1.0%)required accounting or market input is missing
Book value to pricenot computable0.28required accounting or market input is missing
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five yearsnot computable20.3%required accounting or market input is missing
Relative strength against the sector, log excess return(0.20)(0.14)47ahead of 47 of 100 peers

Inputs: EBIT -$49.0M; free cash flow -$45.7M; book equity $214.8M; sales $0; cash $8.3M[15].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero30.0%✓ pass[4,6]
Operating cash flow above zero-$44.8M✗ fail[5]
Return on assets improved70.7 pts✓ pass[4,6,13,16]
Operating cash flow exceeds net income-$58.0M✗ fail[4-5]
Long-term leverage felln/a[1,6,13]
Current ratio improved647.9 pts✓ pass[7-8,17-18]
No new shares issuedn/a
Gross margin improvedn/a
Asset turnover improved(1.6 pts)✗ fail[2,6,13,19]
Cash, filings, liquidity
Cash and equivalents$8.3M[3]
Operating cash flow, four quarters-$53.9M[3,5,20-23]
Months of runway1.8
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing64
10-Q received Aug 6, 2026
Median daily dollar volume$395
63 sessions
Days since newest grade input214

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$172.8M2025-12-312026-03-0910-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$02025-12-312026-03-0910-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$8.3M2026-06-302026-08-0610-Qfiling · viewer · series
4net incomeus-gaap:NetIncomeLoss$13.3M2025-12-312026-03-0910-Kfiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$44.8M2025-12-312026-03-0910-Kfiling · viewer · series
6assetsus-gaap:Assets$44.2M2024-12-312026-03-0910-Kfiling · viewer · series
7current assetsus-gaap:AssetsCurrent$101.1M2025-12-312026-03-0910-Kfiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$10.7M2025-12-312026-03-0910-Kfiling · viewer · series
9retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$110.9M2025-12-312026-03-0910-Kfiling · viewer · series
10operating incomeus-gaap:OperatingIncomeLoss-$49.0M2025-12-312026-03-0910-Kfiling · viewer · series
11book equityus-gaap:StockholdersEquity$151.5M2025-12-312026-03-0910-Kfiling · viewer · series
12liabilitiesus-gaap:Liabilities$21.3M2025-12-312026-03-0910-Kfiling · viewer · series
13assetsus-gaap:Assets$83.9M2023-12-312025-03-3110-Kfiling · viewer · series
14assetsus-gaap:Assets$50.9M2022-12-312024-03-2910-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding90,986,3682026-08-032026-08-0610-Qfiling · viewer · series
16net incomeus-gaap:NetIncomeLoss-$34.1M2024-12-312026-03-0910-Kfiling · viewer · series
17current assetsus-gaap:AssetsCurrent$23.8M2024-12-312026-03-0910-Kfiling · viewer · series
18current liabilitiesus-gaap:LiabilitiesCurrent$8.0M2024-12-312026-03-0910-Kfiling · viewer · series
19revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$1.3M2024-12-312026-03-0910-Kfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$24.1M2026-06-302026-08-0610-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$14.3M2026-03-312026-05-1210-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$28.0M2025-09-302025-11-1410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$14.9M2025-06-302026-08-0610-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.